Amicus Therapeutics (FOLD) Misses Q3 EPS by 10c

Amicus Therapeutics (NASDAQ: FOLD) reported Q3 EPS of ($0.41), $0.10 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $10.9 million versus the consensus estimate of $9.52 million.

For earnings history and earnings-related data on Amicus Therapeutics (FOLD) click here.

You May Also Be Interested In

• Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
• Norwegian Cruise Line rating cut at Mizuho after 'self-inflicted wounds'
• Home Depot beats estimates, reaffirms fiscal 2026 guidance